Novo Nordisk’s (NVO) stock price dropped following Eli Lilly’s announcement of positive Phase 3 trial results for its oral weight loss drug orforglipron—that helped patients shed weight and control blood sugar, comparable to Novo’s (NVO) injectable blockbuster Ozempic.
